Angelman syndrome gene therapies (Asklepios BioPharmaceutical/University of North Carolina at Chapel Hill)

N/A

Report date: 2024/05/11 18:36:08

Base Information

Drug NameAngelman syndrome gene therapies (Asklepios BioPharmaceutical/University of North Carolina at Chapel Hill)
Drug Alias NameAAV-based Angelman syndrome therapies (Asklepios BioPharmaceutical/University of North Carolina at Chapel Hill)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionGene transferenceUbiquitin-like modifier-activating enzyme 3A stimulants
TargetsUbiquitin-like modifier-activating enzyme 3A
Therapy Area/IndicationsAngelman Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of North Carolina At Chapel Hill
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of North Carolina At Chapel Hill
Inactive CompaniesN/A
Active IndicationsAngelman Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A